462 related articles for article (PubMed ID: 26092233)
1. Chemotherapy-associated treatment burden in breast cancer patients receiving lipegfilgrastim or pegfilgrastim: secondary efficacy data from a phase III study.
Gladkov OA; Buchner A; Bias P; Müller U; Elsässer R
Support Care Cancer; 2016 Jan; 24(1):395-400. PubMed ID: 26092233
[TBL] [Abstract][Full Text] [Related]
2. Incidence of bone pain in patients with breast cancer treated with lipegfilgrastim or pegfilgrastim: an integrated analysis from phase II and III studies.
Bondarenko IM; Bias P; Buchner A
Support Care Cancer; 2016 Jan; 24(1):267-273. PubMed ID: 26024743
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy.
Bondarenko I; Gladkov OA; Elsaesser R; Buchner A; Bias P
BMC Cancer; 2013 Aug; 13():386. PubMed ID: 23945072
[TBL] [Abstract][Full Text] [Related]
4. A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel.
Gladkov O; Moiseyenko V; Bondarenko IN; Shparyk Y; Barash S; Adar L; Avisar N
Oncologist; 2016 Jan; 21(1):7-15. PubMed ID: 26668251
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind, active control, multicenter, dose-finding study of lipegfilgrastim (XM22) in breast cancer patients receiving myelosuppressive therapy.
Buchner A; Elsässer R; Bias P
Breast Cancer Res Treat; 2014 Nov; 148(1):107-16. PubMed ID: 25261291
[TBL] [Abstract][Full Text] [Related]
6. Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study.
von Minckwitz G; Kümmel S; du Bois A; Eiermann W; Eidtmann H; Gerber B; Hilfrich J; Huober J; Costa SD; Jackisch C; Grasshoff ST; Vescia S; Skacel T; Loibl S; Mehta KM; Kaufmann M;
Ann Oncol; 2008 Feb; 19(2):292-8. PubMed ID: 17846019
[TBL] [Abstract][Full Text] [Related]
7. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer.
Holmes FA; O'Shaughnessy JA; Vukelja S; Jones SE; Shogan J; Savin M; Glaspy J; Moore M; Meza L; Wiznitzer I; Neumann TA; Hill LR; Liang BC
J Clin Oncol; 2002 Feb; 20(3):727-31. PubMed ID: 11821454
[TBL] [Abstract][Full Text] [Related]
8. Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy.
Kosaka Y; Rai Y; Masuda N; Takano T; Saeki T; Nakamura S; Shimazaki R; Ito Y; Tokuda Y; Tamura K
Support Care Cancer; 2015 Apr; 23(4):1137-43. PubMed ID: 25576433
[TBL] [Abstract][Full Text] [Related]
9. Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study.
Brito M; Esteves S; André R; Isidoro M; Moreira A
Support Care Cancer; 2016 Feb; 24(2):597-603. PubMed ID: 26111956
[TBL] [Abstract][Full Text] [Related]
10. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy.
Green MD; Koelbl H; Baselga J; Galid A; Guillem V; Gascon P; Siena S; Lalisang RI; Samonigg H; Clemens MR; Zani V; Liang BC; Renwick J; Piccart MJ;
Ann Oncol; 2003 Jan; 14(1):29-35. PubMed ID: 12488289
[TBL] [Abstract][Full Text] [Related]
11. The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials.
Wang L; Baser O; Kutikova L; Page JH; Barron R
Support Care Cancer; 2015 Nov; 23(11):3131-40. PubMed ID: 25821144
[TBL] [Abstract][Full Text] [Related]
12. An open-label, randomized, multicenter dose-finding study of once-per-cycle pegfilgrastim versus daily filgrastim in Chinese breast cancer patients receiving TAC chemotherapy.
Zhang W; Jiang Z; Wang L; Li C; Xia J
Med Oncol; 2015 May; 32(5):147. PubMed ID: 25820754
[TBL] [Abstract][Full Text] [Related]
13. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer.
Holmes FA; Jones SE; O'Shaughnessy J; Vukelja S; George T; Savin M; Richards D; Glaspy J; Meza L; Cohen G; Dhami M; Budman DR; Hackett J; Brassard M; Yang BB; Liang BC
Ann Oncol; 2002 Jun; 13(6):903-9. PubMed ID: 12123336
[TBL] [Abstract][Full Text] [Related]
14. Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer.
Kubista E; Glaspy J; Holmes FA; Green MD; Hackett J; Neumann T;
Clin Breast Cancer; 2003 Feb; 3(6):391-8. PubMed ID: 12636878
[TBL] [Abstract][Full Text] [Related]
15. A randomized, multicenter, phase II/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteograstim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10-09.
Lee KH; Kim JY; Lee MH; Han HS; Lim JH; Park KU; Park IH; Cho EK; Yoon SY; Kim JH; Choi IS; Park JH; Choi YJ; Kim HJ; Jung KH; Kim SY; Oh DY; Im SA
Support Care Cancer; 2016 Apr; 24(4):1709-17. PubMed ID: 26423618
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma.
Fust K; Li X; Maschio M; Villa G; Parthan A; Barron R; Weinstein MC; Somers L; Hoefkens C; Lyman GH
Pharmacoeconomics; 2017 Apr; 35(4):425-438. PubMed ID: 27928760
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review.
Pfeil AM; Allcott K; Pettengell R; von Minckwitz G; Schwenkglenks M; Szabo Z
Support Care Cancer; 2015 Feb; 23(2):525-45. PubMed ID: 25284721
[TBL] [Abstract][Full Text] [Related]
18. A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2), a Phase III, Randomized, Double-Blind Trial.
Blackwell K; Donskih R; Jones CM; Nixon A; Vidal MJ; Nakov R; Singh P; Schaffar G; Gascón P; Harbeck N
Oncologist; 2016 Jul; 21(7):789-94. PubMed ID: 27091420
[TBL] [Abstract][Full Text] [Related]
19. A comparative assessment of neutropenia events, healthcare resource use, and costs among cancer patients treated with lipegfilgrastim compared with pegfilgrastim in Germany.
Link H; Thompson SF; Tian M; Haas JS; Meise D; Maas C; Dimitrov S
Support Care Cancer; 2022 Nov; 30(11):9317-9327. PubMed ID: 36076105
[TBL] [Abstract][Full Text] [Related]
20. Febrile neutropenia in adjuvant docetaxel and cyclophosphamide (TC) with prophylactic pegfilgrastim in breast cancer patients: a retrospective analysis.
Ngamphaiboon N; O'Connor TL; Advani PP; Levine EG; Kossoff EB
Med Oncol; 2012 Sep; 29(3):1495-501. PubMed ID: 21818673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]